Burden of disease during quiescent periods in patients with pemphigus

British Journal of Dermatology

Volumn 170, Issue 5, 2014, Pages 1087-1091

  Tabolli, S ^a   Pagliarello, C ^b   Paradisi, A ^a   Cianchini, G ^a   Giannantoni, P ^a   Abeni, D ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

12 ITEM GENERAL HEALTH QUESTIONNAIRE; ADULT; ANXIETY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEPRESSION; EROSION; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEALTH STATUS; HUMAN; IKEDA INDEX; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PEMPHIGUS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK; RISK ASSESSMENT; SKINDEX 17; WELLBEING; ANXIETY DISORDERS; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DEPRESSIVE DISORDER; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SEX DIFFERENCE;

ANXIETY DISORDERS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PEMPHIGUS; QUALITY OF LIFE; QUESTIONNAIRES; SEX FACTORS;

EID: 84901036031     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12836     Document Type: Article

References (22)

1. Sitaru C, Zillikens D,. Mechanism of blister induction by autoantibodies. Exp Dermatol 2005; 14: 861-75.
2. Bystryn IC, Rudolph JL,. Pemphigus. Lancet 2005; 366: 61-75.
3. Terrab Z, Benchikhi H, Maaroufi A, et al,. Quality of life in pemphigus. Ann Dermatol Venereol 2005; 132: 321-8.
4. Mayrshofer F, Hertl M, Stinkraven R, et al,. Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study group. J Dtsch Dermatol Ges 2005; 3: 431-5.
5. Darjani A, Ghanbari A, Sayadi Nejad A,. Comparison of the health-related quality of life of patients suffering from pemphigus with healthy people. J Guilan Univ Med Sci 2008; 17: 1-9.
6. Tabolli S, Mozzetta A, Antinone V, et al,. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using Medical Outcomes Study 36-item short form health survey questionnaire. Br J Dermatol 2008; 158: 1029-34.
7. Paradisi A, Sampogna F, Di Pietro C, et al,. Quality of life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol 2009; 60: 261-9.
8. Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, et al,. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaire. J Dermatol 2012; 39: 141-4.
9. Mazzotti E, Mozzetta A, Antinone V, et al,. Psychological distress and investment in one's appearance in patients with pemphigus. J Eur Acad Dermatol Venereol 2011; 25: 285-9.
10. Chee SN, Murrel DF,. Pemphigus and quality of life. Dermatol Clin 2011; 29: 521-5.
11. Paradisi A, Cianchini G, Lupi F, et al,. Quality of life in patients with pemphigus receiving adjuvant therapy. Clin Exp Dermatol 2012; 37: 626-30.
12. Nijsten TE, Sampogna F, Chren MM, Abeni DD,. Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 1244-50.
13. Picardi A, Abeni D, Mazzotti E, et al,. Screening for psychiatric disorders in patients with skin diseases: a performance study of the 12-item General Health Questionnaire. J Psychosom Res 2004; 57: 219-23.
14. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-40.
15. Ikeda S, Imamura S, Hashimoto I, et al,. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295 (Suppl. 1): S12-16.
16. Murrell DF, Dick S, Ahmed AR, et al,. Consensus statement on definitions of diseases, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.
17. Sampogna F, Chren MM, Melchi CF, et al,. Italian Multipurpose Psoriasis Research on Vital Experiences (Improve) Study Group. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006; 154: 325-31.
18. Sebaratnam DF, Hanna AM, Chee SN, et al,. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. JAMA Dermatol 2013; 149: 1186-91.
19. Rosenbach M, Murrell DF, Bystryn JC, et al,. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 129: 2404-10.
20. Pfutze M, Niedermeier A, Hertl M, Eming R,. Introducing a novel Autoimmune Bullous Skin Disorders Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007; 17: 4-11.
21. Tjokrowidjaja A, Daniel BS, Frew JW, et al,. The development and validation of the treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering diseases. Br J Dermatol 2013; 169: 1000-6.
22. Finlay AY,. The three dimensions of skin diseases burden: 'now', 'long term' and 'family'. Br J Dermatol 2013; 169: 963-4.